<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01519336</url>
  </required_header>
  <id_info>
    <org_study_id>NP28089</org_study_id>
    <nct_id>NCT01519336</nct_id>
  </id_info>
  <brief_title>A Study of Drug-Drug Interaction Between Darunavir and Danoprevir Administered Together With Low-Dose Ritonavir in Healthy Volunteers</brief_title>
  <official_title>A Study to Evaluate the Potential Drug-Drug Interaction Between Darunavir and Danoprevir When Administered Together With Low-Dose Ritonavir in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This randomized, open-label, multiple-dose, 2-period crossover study will evaluate potential&#xD;
      drug-drug interactions between darunavir and danoprevir when administered together with&#xD;
      low-dose ritonavir in healthy volunteers. In Period 1, subjects will be randomized to receive&#xD;
      either darunavir or danoprevir together with low-dose ritonavir for 10 days. In Period 2, all&#xD;
      subjects will receive darunavir plus danoprevir together with ritonavir for 10 days.&#xD;
      Anticipated time on study treatment is 20 days.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of coadministration of darunavir (DRV), danoprevir (DNV) and ritonavir (RTV) on DRV/DNV/RTV pharmacokinetics: Area under the concentration-time curve (AUC)</measure>
    <time_frame>approximately 2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety: Incidence of adverse events</measure>
    <time_frame>approximately 2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>A danoprevir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B darunavir</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>C danoprevir/darunavir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>danoprevir</intervention_name>
    <description>100 mg q12h</description>
    <arm_group_label>A danoprevir</arm_group_label>
    <arm_group_label>C danoprevir/darunavir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>darunavir</intervention_name>
    <description>600 mg q12h</description>
    <arm_group_label>B darunavir</arm_group_label>
    <arm_group_label>C danoprevir/darunavir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ritonavir</intervention_name>
    <description>100 mg q12h</description>
    <arm_group_label>A danoprevir</arm_group_label>
    <arm_group_label>B darunavir</arm_group_label>
    <arm_group_label>C danoprevir/darunavir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy non-smoking male and female adults, 18 - 55 years of age, inclusive&#xD;
&#xD;
          -  Healthy status defined by absence of evidence of any active or chronic disease&#xD;
&#xD;
          -  Medical history without major, recent, or ongoing pathology&#xD;
&#xD;
          -  Weight &gt;/= 55 kg&#xD;
&#xD;
          -  Body mass index (BMI) 18.0 - 32.0 kg/m2&#xD;
&#xD;
          -  Ability and willingness to abstain from alcohol, xanthine-containing beverages or food&#xD;
             (coffee, tea, cola, chocolate, &quot;energy drinks&quot;) from 72 hours prior to entry in the&#xD;
             clinical site center until discharge&#xD;
&#xD;
          -  Females of child-bearing potential and males and their female partners of&#xD;
             child-bearing potential must agree to use 2 forms of contraception, one of which must&#xD;
             be a barrier method, during the study and for 90 days after the last drug&#xD;
             administration. Acceptable barrier forms of contraception are condom and diaphragm;&#xD;
             acceptable non-barrier forms of contraception for this study are non-hormonal&#xD;
             intrauterine device (IUD) and/or spermicide&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating females or males with female partners who are pregnant or&#xD;
             lactating&#xD;
&#xD;
          -  Any history of clinically significant cardiovascular or cerebrovascular disease,&#xD;
             hypertension, and/or infections&#xD;
&#xD;
          -  Positive test for drugs of abuse at screening or prior to admission to the clinical&#xD;
             site during any study period&#xD;
&#xD;
          -  Positive for hepatitis B, hepatitis C or HIV infection&#xD;
&#xD;
          -  Current smokers or subjects who have discontinued smoking less than 6 months prior to&#xD;
             first dose of study medication&#xD;
&#xD;
          -  Use of hormonal contraceptives within 30 days before the first dose of study&#xD;
             medication&#xD;
&#xD;
          -  History of clinically significant drug-related allergy (such as anaphylaxis) or&#xD;
             hepatotoxicity&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>January 24, 2012</study_first_submitted>
  <study_first_submitted_qc>January 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2012</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Darunavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

